NCT05064618View on ClinicalTrials.gov

Investigator-initiated Clinical Trial of MIKE-1

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

August 23, 2021

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions
Pancreatic Cancer
Interventions
DRUG

Am80

medicine taken internally

DRUG

Gemcitabine

Administered intravenously at a dose of 1000mg/m2

DRUG

nab-Paclitaxel

Administered intravenously at a dose of 125mg/m2

Trial Locations (2)

466-8560

RECRUITING

Nagoya University Hospital, Nagoya

Unknown

NOT_YET_RECRUITING

The University of Tokyo Hospital, Tokyo

Sponsors
All Listed Sponsors
collaborator

Japan Agency for Medical Research and Development

OTHER_GOV

lead

Nagoya University

OTHER